We are live on ! Find out more
Parallel Advisors

Parallel Advisors Portfolio holdings

AUM $6.56B Turnover 11.49%
1-Year Est. Return 32.24%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+32.24%
3 Year Est. Return
+108.68%
5 Year Est. Return
+114.41%
10 Year Est. Return
–
AUM
$5B
AUM Growth
+$569M
Cap. Flow
+$104M
Cap. Flow %
2.08%
Top 10 Hldgs %
38.84%
Holding
3,762
New
251
Increased
1,450
Reduced
1,277
Closed
224
Avg Time Held Equity + Options
4.7 years
Top 10 Avg Time Held Equity + Options
2.9 years
Top 20 Avg Time Held Equity + Options
3.8 years
Avg Time Held Equity only
4.7 years
Top 10 Avg Time Held Equity only
2.9 years
Top 20 Avg Time Held Equity only
3.8 years

Sector Composition

Rank Sector Weight
1 Miscellaneous 46.71%
2 Technology 17.21%
3 Healthcare 9.68%
4 Financials 7.2%
5 Communication Services 5.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
FPXI icon
3501
First Trust Exchange-Traded Fund II First Trust International Equity Opportunities ETF
FPXI
$225M
– –
0
– –
2025 Q2
0 quarters
LPL icon
3502
LG Display
LPL
$2.66B
$3 ﹤0.01%
1
-60
-98% -$185
2021 Q2
16 quarters
CCO icon
3503
Clear Channel Outdoor Holdings
CCO
$1.23B
$1 ﹤0.01%
1
– –
2023 Q2
8 quarters
IMUX icon
3504
Immunic
IMUX
$90.9M
– –
0
– –
2018 Q2
28 quarters
WKHS icon
3505
Workhorse Group
WKHS
$32M
– –
0
– –
2025 Q2
0 quarters
AAOI icon
3506
Applied Optoelectronics
AAOI
$7.32B
– –
-11
Closed -$169 –
ABCB icon
3507
Ameris Bancorp
ABCB
$5.24B
– –
-2
Closed -$115 –
AESI icon
3508
Atlas Energy Solutions
AESI
$1.38B
– –
-24
Closed -$428 –
AIN icon
3509
Albany International
AIN
$1.72B
– –
-1
Closed -$69 –
ALDX icon
3510
Aldeyra Therapeutics
ALDX
$47.7M
– –
-30
Closed -$173 –
ALLK icon
3511
DELISTED
Allakos
ALLK
– –
-770
Closed -$175 –
ALLO icon
3512
Allogene Therapeutics
ALLO
$449M
– –
-114
Closed -$166 –
ALRM icon
3513
Alarm.com
ALRM
$2.78B
– –
-6
Closed -$334 –
ALUR icon
3514
DELISTED
Allurion Technologies
ALUR
– –
-10
Closed -$32 –
ALZN icon
3515
Alzamend Neuro
ALZN
$6.51M
– –
0
– -$3
2023 Q4
6 quarters
AMPX icon
3516
Amprius Technologies
AMPX
$1.17B
– –
-5,242
Closed -$14K –
APOG icon
3517
Apogee Enterprises
APOG
$849M
– –
-460
Closed -$21.3K –
AQMS icon
3518
Aqua Metals
AQMS
$6.18M
– –
-836
Closed -$15.6K –
ARIS icon
3519
DELISTED
Aris Water Solutions
ARIS
– –
-32
Closed -$1.02K –
AROW icon
3520
Arrow Financial
AROW
$670M
– –
-6
Closed -$158 –
ARQT icon
3521
Arcutis Biotherapeutics
ARQT
$3.32B
– –
-14
Closed -$219 –
ASPN icon
3522
Aspen Aerogels
ASPN
$428M
– –
-3,640
Closed -$23.3K –
ASRT icon
3523
DELISTED
Assertio
ASRT
– –
-166
Closed -$1.68K –
ATLX icon
3524
Atlas Lithium Corp
ATLX
$59.3M
– –
-100
Closed -$517 –
AUPH icon
3525
Aurinia Pharmaceuticals
AUPH
$2.21B
– –
-43
Closed -$346 –

Similar funds

Parallel Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Parallel Advisors held 3,762 positions worth $5B, up 13% from $4.43B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Parallel Advisors's Q2 2025 filing shows 251 new, 1,450 increased, 1,277 reduced and 224 closed positions. Its largest new stake was Vanguard 0-3 Month Treasury Bill ETF: 32,722 shares worth $2.47M. The largest sale was Corcept Therapeutics, an estimated $7.34M.

By sector, the portfolio is most concentrated in Miscellaneous at 47% of assets, down from 47% a quarter earlier, followed by Technology and Healthcare.

  • Parallel Advisors's largest Q2 2025 buy was Vanguard 0-3 Month Treasury Bill ETF: 32,722 shares worth $2.47M.
  • Parallel Advisors added most to iShares Core S&P 500 ETF in Q2 2025, an estimated $18.4M increase.
  • Parallel Advisors's biggest Q2 2025 reduction was Corcept Therapeutics, cutting an estimated $7.34M.
  • Parallel Advisors fully exited Discover Financial Services in Q2 2025, selling an estimated $1.22M.
  • Parallel Advisors's ten largest holdings make up 39% of its $5B portfolio in Q2 2025.
  • Parallel Advisors opened 251 new positions and closed 224 in Q2 2025.
  • Parallel Advisors's portfolio value rose 13% quarter-over-quarter to $5B.

Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.